Lithium therapy and weight change in people with bipolar disorder: A systematic review and meta-analysis
•Lithium is the gold standard treatment for bipolar disorder.•Weight change with lithium was not clinically or statistically significant.•Weight change with lithium did not differ from placebo.•Weight gain was greater with some active comparators than with lithium. Lithium remains the gold standard...
Gespeichert in:
Veröffentlicht in: | Neuroscience and biobehavioral reviews 2022-03, Vol.134, p.104266-104266, Article 104266 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •Lithium is the gold standard treatment for bipolar disorder.•Weight change with lithium was not clinically or statistically significant.•Weight change with lithium did not differ from placebo.•Weight gain was greater with some active comparators than with lithium.
Lithium remains the gold standard maintenance treatment for Bipolar Disorder (BD). However, weight gain is a side effect of increasing relevance due to its metabolic implications. We conducted a systematic review and meta-analysis aimed at summarizing evidence on the use of lithium and weight change in BD. We followed the PRISMA methodology, searching Pubmed, Scopus and Web of Science. From 1003 screened references, 20 studies were included in the systematic review and 9 included in the meta-analysis. In line with the studies included in the systematic review, the meta-analysis revealed that weight gain with lithium was not significant, noting a weight increase of 0.462 Kg (p = 0158). A shorter duration of treatment was significantly associated with more weight gain. Compared to placebo, there were no significant differences in weight gain. Weight gain was significantly lower with lithium than with active comparators. This work reveals a low impact of lithium on weight change, especially compared to some of the most widely used active comparators. Our results could impact clinical decisions. |
---|---|
ISSN: | 0149-7634 1873-7528 |
DOI: | 10.1016/j.neubiorev.2021.07.011 |